Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2019 Results - Earnings Call Transcript

Kala Pharmaceuticals had received a CRL for its corticosteroid drug known as KPI-121 0.25% for the treatment of dry eye disease.

Kala Still Has A Shot To Reach Its Goal For Approval After Latest Setback

EyePoint Pharmaceuticals

Novartis

Ocular Therapeutix

The growing eye industry is something investors can’t ignore.

Keep Your Eye on These 4 Healthcare Stocks

Kala Pharmaceuticals received a CRL for KPI-121 0.25%, but already dropped a lot leading up to its PDUFA date.

The Market Is Sour On Kala Pharmaceuticals Despite Insider Support

The company finally has a drug product on the market, but it didn't live up to Wall Street's expectations in the second quarter.

Kala Pharmaceuticals Reports Disappointing Q2 Sales

Kala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q2 2019 Results - Earnings Call Transcript

Kala Pharma (KALA) delivered earnings and revenue surprises of 5.41% and -21.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates

Kala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript

Kala Pharma (KALA) delivered earnings and revenue surprises of 17.28% and 43.78%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates

HEXO Corp

iPic Entertainment

Northern Oil and Gas

Range Resources

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Smoking Hot Stocks Trading Under $10 With Gigantic Upside Potential

News for Kala Pharmaceuticals Stock (KALA)